Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 2.94 7.30% 0.20
LXRX closed up 7.3 percent on Tuesday, September 17, 2019, on 3.98 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical LXRX trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
Doji - Bearish? Reversal 0.00%

Older signals for LXRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Health Biopharmaceutical Life Sciences Pharmaceutical Industry Diabetes Drug Discovery Monoclonal Antibodies Clinical Trial Rheumatoid Arthritis Glaucoma Ulcerative Colitis Irritable Bowel Syndrome Treatment Of Glaucoma Biotie Therapies Genentech Human Disease
Is LXRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.51
52 Week Low 1.125
Average Volume 2,113,428
200-Day Moving Average 5.3291
50-Day Moving Average 2.71
20-Day Moving Average 1.64
10-Day Moving Average 1.955
Average True Range 0.3016
ADX 49.19
+DI 48.4301
-DI 14.3801
Chandelier Exit (Long, 3 ATRs ) 2.5052
Chandelier Exit (Short, 3 ATRs ) 2.1248
Upper Bollinger Band 2.7094
Lower Bollinger Band 0.5706
Percent B (%b) 1.11
BandWidth 130.414634
MACD Line 0.0498
MACD Signal Line -0.2275
MACD Histogram 0.2773
Fundamentals Value
Market Cap 311.29 Million
Num Shares 106 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -2.21
Price-to-Sales 13.10
Price-to-Book 9.99
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.86
Resistance 3 (R3) 3.91 3.66 3.70
Resistance 2 (R2) 3.66 3.43 3.63 3.65
Resistance 1 (R1) 3.30 3.28 3.48 3.25 3.60
Pivot Point 3.05 3.05 3.14 3.02 3.05
Support 1 (S1) 2.69 2.82 2.87 2.64 2.28
Support 2 (S2) 2.44 2.67 2.41 2.23
Support 3 (S3) 2.08 2.44 2.18
Support 4 (S4) 2.03